Zentek CEO on Revolutionizing Graphite Purity & Commercializing Disruptive Filtration Technology

Zentek Ltd. (NASDAQ: ZTEK | TSXV: ZEN) is poised to revolutionize the graphite and critical mineral sectors, underscored by CEO Greg Fenton’s statement: "It's probably the most exciting time in the history of Zentek." In a recent interview with InvestorNews host Tracy Hughes, Fenton highlighted the Albany graphite deposit as uniquely positioned to address critical mineral demands. Located in central Ontario, Albany has demonstrated exceptional purity, achieving “five nines” (99.999+%) purity in graphite through an environmentally friendly, two-step thermal process, bypassing intermediate hydrometallurgical stages. According to Fenton, this method positions Albany graphite competitively for "the highest value markets," notably nuclear, military, and lithium-ion battery applications, emphasizing the deposit’s strategic significance, especially with growing interest from the United States, where Zentek recently engaged in discussions with Congress regarding the resource’s national security importance.The intersection of technology and critical minerals further differentiates Zentek. CEO Greg Fenton noted that Zentek’s proprietary ZenGUARD™ antimicrobial technology, applied to HVAC filters, is nearing commercialization, with initial revenues anticipated by the end of March 2025. "We announced that we will be commercializing by the end of the first quarter to early adopters," confirmed Fenton, emphasizing this milestone as a pivotal achievement for Zentek. Recently completed shelf-life efficacy testing demonstrated that ZenGUARD™ Enhanced Air Filters maintain consistent viral filtration efficiency after 20 months, solidifying the company's position in the medical device market. Zentek’s ZenGUARD™ filters will soon enter commercialization under a Class I medical device establishment license, fulfilling a critical demand for safer and more efficient air filtration systems. Looking ahead, Zentek is not only advancing its graphite and filtration technologies but also exploring new opportunities in biotechnology. Fenton indicated upcoming developments in Zentek’s biotech division, specifically its therapeutic solution for avian influenza (H5N1), supported by a grant from Innovation Solutions Canada. He concluded optimistically, "We're very, very excited about where we are as a company," highlighting Zentek's strategic alignment with burgeoning interest in critical minerals, advanced filtration, and healthcare innovation, solidifying the company's position as a leader at the intersection of technology and resources.